Coya Therapeutics

Update in progress

COYA (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Coya Therapeutics is a clinical-stage biotech focused on enhancing regulatory T cells (Tregs). Its lead program, COYA 302, is a subcutaneous biologic designed to boost Treg function while reducing effector T cells and activated macrophages, in Phase 2 for ALS and under exploration for FTD, AD, and PD. Preclinical programs include COYA 301 (low-dose IL-2 for AD), COYA 303 (IL-2 plus GLP-1 receptor agonist), and Treg-derived exosomes COYA 201/206 and COYA 101. Based in Houston, TX.

Company score

Sentiment: 0.32; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.30; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.13; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.22; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive